2023 Was a troublesome yr to the biopharma field, with a number of firms downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences market while in the latter Component of 2023 and possess ongoing https://sites.google.com/view/bio-sites/blog